DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Three oral GLP-1s FDA-approved December 2025 to May 2026 — Foundayo, Wegovy pill, Ozempic pill — joined the legacy Rybelsus. The injection era is no longer the only option.
First small-molecule oral GLP-1 (not peptide). No food/water timing. Manufacturable at scale, likely cheapest pathway by 2027. Weight-loss indication filing expected late 2026.
High-dose oral semaglutide formulated for weight loss. OASIS-1 Phase 3 approached injection efficacy. Empty-stomach rule is adherence trade-off.
T2D-indicated. Lower weight-loss outcomes than injection but eliminates needle. WW Med+ launched broadest oral dispensing May 2026.
Original oral semaglutide. Lower dose ceiling than Rybelsus HD. Most predictable T2D coverage.
Switching from injectable Wegovy or Ozempic to oral typically requires fresh titration. Oral half-life and bioavailability differ. Most prescribers restart at lowest oral dose and titrate up over 16 weeks. Weight loss may pause briefly during transition.
Editorial summary, updated quarterly. FDA approvals and pricing shift. Last reviewed 2026-05-26.